logo
Array's (NASDAQ:ARRY) Q1: Strong Sales, Stock Soars

Array's (NASDAQ:ARRY) Q1: Strong Sales, Stock Soars

Yahoo06-05-2025
We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Array's performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 21.2% annually. Array isn't alone in its struggles as the Renewable Energy industry experienced a cyclical downturn, with many similar businesses observing lower sales at this time.
A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Array's sales grew at a weak 1.2% compounded annual growth rate over the last five years. This was below our standards and is a tough starting point for our analysis.
'ARRAY is off to a great start for 2025 with first quarter high double digits revenue growth compared with the first quarter of 2024, and achieving the second largest quarter of volume shipped since 2023, indicating solid market share recovery and the strength of our execution capabilities. We are now able to provide customers with quotes for our 100% domestic content trackers under Table I of the Inflation Reduction Act ('IRA'), an important milestone for ARRAY, reflecting our continued commitment to supply chain resilience and ability to minimize effects of geopolitical uncertainty, including tariffs."
Free Cash Flow was -$15.41 million, down from $45.12 million in the same quarter last year
EBITDA guidance for the full year is $190 million at the midpoint, above analyst estimates of $186.1 million
The company reconfirmed its revenue guidance for the full year of $1.1 billion at the midpoint
Is now the time to buy Array? Find out in our full research report .
Solar tracking systems manufacturer Array (NASDAQ:ARRY) announced better-than-expected revenue in Q1 CY2025, with sales up 97.1% year on year to $302.4 million. The company's full-year revenue guidance of $1.1 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP profit of $0.13 per share was 47.4% above analysts' consensus estimates.
Story Continues
Array Year-On-Year Revenue Growth
This quarter, Array reported magnificent year-on-year revenue growth of 97.1%, and its $302.4 million of revenue beat Wall Street's estimates by 14.3%.
Looking ahead, sell-side analysts expect revenue to grow 3.9% over the next 12 months. While this projection implies its newer products and services will spur better top-line performance, it is still below average for the sector.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Operating Margin
Array was roughly breakeven when averaging the last five years of quarterly operating profits, one of the worst outcomes in the industrials sector. This result isn't too surprising given its low gross margin as a starting point.
Analyzing the trend in its profitability, Array's operating margin decreased by 20.9 percentage points over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Array's performance was poor no matter how you look at it - it shows that costs were rising and it couldn't pass them onto its customers.
Array Trailing 12-Month Operating Margin (GAAP)
This quarter, Array generated an operating profit margin of 9%, up 3.5 percentage points year on year. The increase was encouraging, and because its gross margin actually decreased, we can assume it was more efficient because its operating expenses like marketing, R&D, and administrative overhead grew slower than its revenue.
Earnings Per Share
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Array, its EPS declined by 18% annually over the last five years while its revenue grew by 1.2%. This tells us the company became less profitable on a per-share basis as it expanded.
Array Trailing 12-Month EPS (Non-GAAP)
Diving into the nuances of Array's earnings can give us a better understanding of its performance. As we mentioned earlier, Array's operating margin improved this quarter but declined by 20.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business.
For Array, its two-year annual EPS declines of 77.3% show it's continued to underperform. These results were bad no matter how you slice the data.
In Q1, Array reported EPS at $0.13, up from negative $0.17 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Array's full-year EPS of negative $0.34 will flip to positive $0.65.
Key Takeaways from Array's Q1 Results
We were impressed by how significantly Array blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also excited its guidance topped Wall Street's estimates. Zooming out, we think this quarter featured some important positives. The stock traded up 9.8% to $5.40 immediately after reporting.
Array put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

Yahoo

time38 minutes ago

  • Yahoo

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges
Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges

Yahoo

time38 minutes ago

  • Yahoo

Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges

We recently published . ABC is one of the best healthcare stocks. Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best healthcare stocks. It is a Medicare Advantage insurer that leverages its AI-powered Clover Assistant platform to improve health outcomes, particularly for chronic conditions such as congestive heart failure. Its PPO-focused model offers broader network access compared to typical HMO plans, aiming to reduce hospitalizations and readmissions through advanced analytics and clinical decision support. In Q2 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. Insurance revenue grew 34% to about $470 million, with adjusted EBITDA and net income both at roughly $17 million, maintaining profitability despite elevated sector-wide medical costs. Clover Assistant has demonstrated measurable impact, including an 18% reduction in hospitalizations and 25% fewer 30-day readmissions for heart failure patients under its care model. The business plans to use these results as a competitive differentiator and is expanding the platform to other risk-bearing organizations. Photo by National Cancer Institute on Unsplash The corporation also improved its Medicare star ratings, with PPO plans projected to rise from 3.5 stars in 2025 to 4.0 stars in 2026, boosting reimbursement potential and market competitiveness. While facing rising costs from supplemental benefits and regulatory changes, Clover Health Investments, Corp. (NASDAQ:CLOV) is pursuing cost-efficiency measures such as renegotiating partnerships and expects these efforts, along with regulatory adjustments, to help ease pressures by 2026. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

Yahoo

time38 minutes ago

  • Yahoo

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

We recently published . GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best healthcare stocks. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription drug prices and access discounts, while also expanding into telehealth and other healthcare services. A major recent focus is the company's growth in pharma manufacturer solutions, where it partners with drug makers for targeted advertising and patient access programs. In Q2 2025, revenue from this segment rose 32%, prompting GoodRx to raise its full-year growth forecast from 20% to 30%. This shift diversifies its business beyond traditional prescription savings cards and strengthens its role as a key marketing partner for pharmaceutical companies. Copyright: zneb076 / 123RF Stock Photo GoodRx Holdings, Inc. (NASDAQ:GDRX) is also broadening its consumer offerings through subscription-based services, including a new program for affordable erectile dysfunction medications (Sildenafil and Tadalafil). These initiatives support its mission of lowering out-of-pocket drug costs while enhancing direct-to-consumer healthcare access. Its telehealth platform remains an important but underutilized growth channel, with potential for further expansion. Additionally, GoodRx Holdings, Inc. (NASDAQ:GDRX) is undergoing a brand relaunch and implementing targeted marketing strategies to boost engagement and market share. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store